Effect of warfarin on survival in Scleroderma-associated Pulmonary Arterial Hypertension (SSc-PAH) and idiopathic PAH. Belief elicitation for bayesian priors

Journal of Rheumatology

Volumn 38, Issue 3, 2011, Pages 462-469

  Johnson, Sindhu R ^a,b   Granton, John T ^a   Tomlinson, George A ^b,c   Grosbein, Haddas A ^d   Hawker, Gillian A ^b,e   Feldman, Brian M ^b,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

Bayesian; Belief elicitation; Priors; Pulmonary hypertension; Scleroderma; Warfarin

Indexed keywords

WARFARIN;

ARTICLE; BAYES THEOREM; DISEASE DURATION; FEMALE; FUNCTIONAL STATUS; HUMAN; IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION; LUNG ARTERY PRESSURE; MALE; MEDICAL SPECIALIST; PERIPHERAL VASCULAR DISEASE; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PULMONARY HYPERTENSION; SCLERODERMA ASSOCIATED PULMONARY ARTERIAL HYPERTENSION; SEX; SURVIVAL; SURVIVAL TIME;

ANTICOAGULANTS; BAYES THEOREM; HUMANS; HYPERTENSION, PULMONARY; MALE; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; SCLERODERMA, SYSTEMIC; SURVIVAL RATE; WARFARIN;

EID: 79952431264     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100632     Document Type: Article

References (36)

1. Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002;81:154-67. (Pubitemid 34218570)
2. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996;35:989-93.
3. Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006;92:926-32. (Pubitemid 43974055)
4. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9.
5. Welsh CH, Hassell KL, Badesch DB, Kressin DC, Marlar RA. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996;110:710-7. (Pubitemid 27009296)
6. Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest 2006;130:545-52. (Pubitemid 44267025)
7. Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J 2006;28:999-1004. (Pubitemid 46331971)
8. Roman A, Rodes-Cabau J, Lara B, Bravo C, Monforte V, Pallissa E, et al. [Clinico-hemodynamic study and treatment of 44 patients with primary pulmonary hypertension]. Med Clin (Barc) 2002;118:761-6.
9. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70:580-7. (Pubitemid 14020655)
10. Kawut SM, Horn EM, Berekashvili KK, Garofano RP, Goldsmith RL, Widlitz AC, et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 2005;95:199-203. (Pubitemid 40092084)
11. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
12. Ogata M, Ohe M, Shirato K, Takishima T. Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension. Jpn Circ J 1993;57:63-9. (Pubitemid 23071864)
13. Storstein O, Efskind L, Muller C, Rokseth R, Sander S. Primary pulmonary hypertension with emphasis on its etiology and treatment. Acta Med Scand 1966;179:197-212.
14. Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997;112:714-21. (Pubitemid 27410708)
15. Johnson SR, Feldman BM, Pope JE, Tomlinson GA. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. J Rheumatol 2009;36:323-9.
16. Gifford F. Uncertainty about clinical equipoise. Clinical equipoise and the uncertainty principles both require further scrutiny. BMJ 2001;322:795.
17. Senn S. Testing for baseline balance in clinical trials. Stat Med 1994;13:1715-26. (Pubitemid 24284854)
18. Austin PC. Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: a systematic review and suggestions for improvement. J Thorac Cardiovasc Surg 2007;134:1128-35.
19. Austin PC, Brunner LJ, Hux JE. Bayeswatch: an overview of Bayesian statistics. J Eval Clin Pract 2002;8:277-86. (Pubitemid 34685904)
20. Chaloner K. Elicitation of prior distributions. In: Berry DA, Stangl DK, editors. Bayesian biostatistics. New York: Marcel Dekker Inc.; 1996:141-56.
21. Chaloner K, Rhame FS. Quantifying and documenting prior beliefs in clinical trials. Stat Med 2001;4:581-600. (Pubitemid 32166421)
22. Spiegelhalter DJ, Freedman LS. A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion. Stat Med 1986;5:1-13. (Pubitemid 16132211)
23. Spiegelhalter DJ. Incorporating Bayesian ideas into health-care evaluation. Statist Sci 2004;19:156-74. (Pubitemid 39056884)
24. O'Hagan A, Buck CE, Daneshkhah A, Eiser JR, Garthwaite PH, Jenkinson DJ, et al. Uncertain judgements. Eliciting experts' probabilities. Chichester: John Wiley & Sons Ltd.; 2006.
25. Johnson SR, Tomlinson GA, Hawker GA, Granton JT, Feldman BM. Methods to elicit beliefs for Bayesian priors: a systematic review. J Clin Epidemiol 2010;63:355-69.
26. Norman GR, Streiner DL. Biostatistics. The bare essentials. 3rd ed. Hamilton: BC Decker; 2008.
27. Johnson SR, Tomlinson GA, Hawker GA, Granton JT, Grosbein HA, Feldman BM. A valid and reliable belief elicitation method for Bayesian priors. J Clin Epidemiol 2010;63:370-83.
28. Johnson SR, Swiston JR, Granton JT. Prognostic factors for survival in scleroderma associated pulmonary arterial hypertension. J Rheumatol 2008;35:1584-90.
29. Warn DE, Thompson SG, Spiegelhalter DJ. Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales. Stat Med 2002;21:1601-23. (Pubitemid 34746065)
30. Sung L, Hayden J, Greenberg ML, Koren G, Feldman BM, Tomlinson GA. Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study. J Clin Epidemiol 2005;58:261-8. (Pubitemid 40249468)
31. R Development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2005.
32. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Statist Comput 2000;10:325-37.
33. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003;48:516-22. (Pubitemid 36278021)
34. Mukerjee D, St. George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-93. (Pubitemid 37323574)
35. Johnson SR, Feldman BM, Hawker GA. Classification criteria for systemic sclerosis subsets. J Rheumatol 2007;34:1855-63. (Pubitemid 350067646)
36. Leidy NK. Evolving concepts in the measurement of treatment effects. Proc Am Thorac Soc 2006;3:212-7. (Pubitemid 43668184)